FDA Approves Imbruvica/Rituxan Combination for Rare Blood Cancer

The co-marketers of Imbruvica® (ibrutinib), AbbVie and Janssen (Johnson & Johnson), said today that the FDA has approved their drug in combination with the Genentech/Biogen co-marketed Rituxan® (rituximab) as the first non-chemotherapy combination treatment for the rare blood cancer Waldenström's macroglobulinemia (WM).The approval marks the ninth FDA authorization since January 2015 for Imbruvica, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor developed and commercia